公开(公告)号：US09801935B2

公开(公告)日：2017-10-31

申请号：US15290349

申请日：2016-10-11

申请人： Seqirus UK Limited

发明人： Derek O'Hagan ,  Manmohan Singh ,  Sung-Yun Kwon

IPC分类号： A61M5/158 ,  A61K39/145 ,  G01N33/68 ,  A61M37/00 ,  A61B17/20 ,  A61K39/00 ,  A61B17/00

CPC分类号： A61K39/145 ,  A61B17/205 ,  A61B2017/00004 ,  A61K9/146 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/70 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0046 ,  A61M2202/30 ,  C12N2760/16111 ,  C12N2760/16134 ,  C12N2760/16211 ,  C12N2760/16234 ,  G01N33/68 ,  G01N2333/11

摘要： Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunizing against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine.

公开(公告)号：US20170119872A1

公开(公告)日：2017-05-04

申请号：US15290349

申请日：2016-10-11

申请人： Seqirus UK Limited

发明人： Derek O'HAGAN ,  Manmohan SINGH ,  Sung-Yun KWON

IPC分类号： A61K39/145 ,  A61M37/00 ,  A61B17/20 ,  G01N33/68

CPC分类号： A61K39/145 ,  A61B17/205 ,  A61B2017/00004 ,  A61K9/146 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/70 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0046 ,  A61M2202/30 ,  C12N2760/16111 ,  C12N2760/16134 ,  C12N2760/16211 ,  C12N2760/16234 ,  G01N33/68 ,  G01N2333/11

摘要： Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunising against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine.

公开(公告)号：US20120015344A1

公开(公告)日：2012-01-19

申请号：US13068427

申请日：2011-05-11

申请人： Evangelyn C. Alocilia ,  Tracy L. Kamikawa ,  Dorothy Elizabeth Scott ,  Michael C. Kennedy ,  Pei Zhang ,  Malgorzata Mikolajczyk ,  Lilin Zhong

发明人： Evangelyn C. Alocilia ,  Tracy L. Kamikawa ,  Dorothy Elizabeth Scott ,  Michael C. Kennedy ,  Pei Zhang ,  Malgorzata Mikolajczyk ,  Lilin Zhong

IPC分类号： C12Q1/70 ,  C08G73/02 ,  C12M1/34 ,  C12N7/00 ,  B82Y15/00

CPC分类号： C08G73/0266 ,  B82Y15/00 ,  C08G2261/3221 ,  C08G2261/3223 ,  C08G2261/94 ,  C08G2261/964 ,  C08K3/22 ,  C08L65/00 ,  C12N2760/16111 ,  C12N2760/16211 ,  C12N2760/16311 ,  C08L79/02

摘要： The disclosure generally relates to a particulate composition formed from a conductive polymer bound to magnetic nanoparticles. The particulate composition can be formed into a biologically enhanced, electrically active magnetic (BEAM) nanoparticle composition by further including a binding pair member (e.g., an antibody or a fragment thereof that specifically recognizes a virus strain or a virus surface protein) bound to the conductive polymer of the particulate composition. The disclosure further provides compositions, kits, detection apparatus, and methods for detecting specific viral strains including those with pandemic potential. In the various embodiments, a triplex including the BEAM nanoparticle, a virus or virally derived material (e.g. strain- and/or strain subtype specific viral surface protein or fragments thereof), and a viral strain subtype-specific binding pair member (e.g., a glycan that recognizes a specific virus strain subtype) is formed and detected, such as by use of a biosensor.

摘要翻译： 本发明一般涉及由与磁性纳米颗粒结合的导电聚合物形成的颗粒组合物。 颗粒组合物可以通过进一步包括结合对成员（例如，特异性识别病毒株或病毒表面蛋白的抗体或其片段）结合到生物增强的电活性磁性（BEAM）纳米颗粒组合物 导电聚合物。 本公开进一步提供了组合物，试剂盒，检测装置和用于检测特定病毒株的方法，包括具有大流行潜力的病毒株。 在各种实施方案中，包括BEAM纳米颗粒，病毒或病毒衍生的材料（例如菌株和/或菌株亚型特异性病毒表面蛋白或其片段）和病毒株亚型特异性结合对成员（例如， 形成并检测识别特定病毒株亚型的聚糖，例如通过使用生物传感器。

公开(公告)号：US20170313765A1

公开(公告)日：2017-11-02

申请号：US15520510

申请日：2015-10-28

申请人： Novartis AG ,  The General Hospital Corporation

发明人： Andrew Geall ,  Galit Alter ,  Todd Suscovich

IPC分类号： C07K16/10 ,  A61K39/145 ,  A61K39/12 ,  A61K39/00 ,  C12N15/00 ,  C07K16/00

CPC分类号： C07K16/1018 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/515 ,  C07K16/00 ,  C07K16/10 ,  C07K2317/10 ,  C12N15/00 ,  C12N2760/16211 ,  C12N2770/32043 ,  C12N2770/36143 ,  C12N2830/20

摘要： The present invention relates to methods exogenous nucleic acid molecules, such as RNA, that encode an antibody or antigen-binding fragment of an antibody, and optionally encode a cellular modulation factor and/or a potentiation factor. The cellular modulation factor is a factor that results in increased expression of the antibody and/or antigen-binding fragment. The potentiation factor is a factor that provides desired antibody effector or other properties. The exogenous nucleic acid molecules can be DNA or RNA, as mRNA (including self-replication RNA and non-self-replicating RNA). The invention also relates method for administering the exogenous nucleic acid molecules to a subject to achieve production of the encoded antibody or antigen-binding fragment in the subject to provide, for example, prophylactic or therapeutic passive immunity.

公开(公告)号：US20140322700A1

公开(公告)日：2014-10-30

申请号：US14284259

申请日：2014-05-21

申请人： Holger KOST

发明人： Holger KOST

IPC分类号： C12Q3/00 ,  C12N7/00 ,  G01N33/569

CPC分类号： C12Q3/00 ,  C12N7/00 ,  C12N2760/16011 ,  C12N2760/16111 ,  C12N2760/16211 ,  C12Q1/04 ,  G01N33/56983 ,  G01N2333/07 ,  G01N2333/11

摘要： The invention provides a method for determining the concentration of virus particles and/or virus antigens in a sample. In particular, the invention relates to determining the concentration of influenza virus particles/influenza virus antigens in a sample. The invention further relates to the use of an ion-exchange matrix for the determination of the concentration of virus particles and/or virus antigens in a sample.

摘要翻译： 本发明提供了一种确定样品中病毒颗粒和/或病毒抗原浓度的方法。 特别地，本发明涉及确定样品中流感病毒颗粒/流感病毒抗原的浓度。 本发明还涉及离子交换基质用于测定样品中病毒颗粒和/或病毒抗原浓度的用途。

公开(公告)号：US08012737B2

公开(公告)日：2011-09-06

申请号：US12370110

申请日：2009-02-12

申请人： Qi Dang ,  Richard Schwartz

发明人： Qi Dang ,  Richard Schwartz

IPC分类号： C12N7/02 ,  A61K39/187

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/145 ,  C12N2760/16211 ,  C12N2760/16234 ,  C12N2760/16261

摘要： Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.

摘要翻译： 提供了用于优化和生产适合作为流感疫苗的鸡蛋和宿主细胞中的流感病毒例如流感乙型流感病毒株的方法和组合物。

公开(公告)号：US09517205B2

公开(公告)日：2016-12-13

申请号：US13817814

申请日：2011-08-19

申请人： Derek O'Hagan ,  Manmohan Singh ,  Sung-Yun Kwon

发明人： Derek O'Hagan ,  Manmohan Singh ,  Sung-Yun Kwon

IPC分类号： A61M5/158 ,  A61K9/14 ,  A61B17/20 ,  A61K39/145 ,  A61K39/12 ,  A61B17/00 ,  A61K39/00 ,  A61M37/00

CPC分类号： A61K39/145 ,  A61B17/205 ,  A61B2017/00004 ,  A61K9/146 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/70 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0046 ,  A61M2202/30 ,  C12N2760/16111 ,  C12N2760/16134 ,  C12N2760/16211 ,  C12N2760/16234 ,  G01N33/68 ,  G01N2333/11

摘要： Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunizing against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine.

摘要翻译： 流感疫苗使用固体可生物降解的微针进行施用。 微针由流感疫苗与固体赋形剂组合制成，并且在穿透皮肤后，它们原位溶解并将疫苗释放到免疫系统中。 流感疫苗是（i）纯化的流感病毒表面抗原疫苗，而不是活疫苗或全病毒或分裂灭活疫苗（ii）由在细胞培养物中生长的病毒而不是鸡蛋制备的流感疫苗，（iii） 单价流感疫苗，例如 用于免疫大流行性毒株，（iv）二价疫苗，（v）四价或> 4价疫苗，（vi）无汞疫苗或（vii）无明胶疫苗。

公开(公告)号：US20130287832A1

公开(公告)日：2013-10-31

申请号：US13817814

申请日：2011-08-19

申请人： Derek O'Hagan ,  Manmohan Singh ,  Sung-Yun Kwon

发明人： Derek O'Hagan ,  Manmohan Singh ,  Sung-Yun Kwon

IPC分类号： A61K9/14

CPC分类号： A61K39/145 ,  A61B17/205 ,  A61B2017/00004 ,  A61K9/146 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/70 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0046 ,  A61M2202/30 ,  C12N2760/16111 ,  C12N2760/16134 ,  C12N2760/16211 ,  C12N2760/16234 ,  G01N33/68 ,  G01N2333/11

摘要： Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunizing against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine.

摘要翻译： 流感疫苗使用固体可生物降解的微针进行施用。 微针由流感疫苗与固体赋形剂组合制成，并且在穿透皮肤后，它们原位溶解并将疫苗释放到免疫系统中。 流感疫苗是（i）纯化的流感病毒表面抗原疫苗，而不是活疫苗或全病毒或分裂灭活疫苗（ii）由在细胞培养物中生长的病毒而不是鸡蛋制备的流感疫苗，（iii） 单价流感疫苗，例如 用于免疫大流行性毒株，（iv）二价疫苗，（v）四价或> 4价疫苗，（vi）无汞疫苗或（vii）无明胶疫苗。

公开(公告)号：US20110206727A1

公开(公告)日：2011-08-25

申请号：US13056962

申请日：2009-05-15

申请人： Denis Leclerc

发明人： Denis Leclerc

IPC分类号： A61K39/295 ,  A61P37/04 ,  A61P31/16

CPC分类号： A61K39/0275 ,  A61K2039/523 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/70 ,  C12N2760/16111 ,  C12N2760/16211 ,  C12N2770/26023 ,  Y02A50/482 ,  Y02A50/484

摘要： A multivalent vaccine composition that comprises a papaya mosaic virus (PapMV) component and one or more antigens is provided. The composition can further optionally comprise a Salmonella spp. porin component. The PapMV component can be PapMV or PapMV virus-like particles (VLPs). The porin component can be a Salmonella spp. OmpC, OmpF or a combination thereof, and can be combined with the PapMV component or conjugated to the PapMV component. The PapMV component in the multivalent vaccine composition functions as an adjuvant and/or an immunostimulant with respect to the one or more antigens. Use of the multivalent vaccine compositions to provide protection against a plurality of strains of a pathogen, or against more than one pathogen, are also provided.

摘要翻译： 提供了包含番木瓜花叶病毒（PapMV）组分和一种或多种抗原的多价疫苗组合物。 组合物还可以任选地包含沙门氏菌属。 孔蛋白成分。 PapMV组分可以是PapMV或PapMV病毒样颗粒（VLP）。 孔蛋白组分可以是沙门氏菌属。 OmpC，OmpF或其组合，并且可以与PapMV组分组合或与PapMV组分缀合。 多价疫苗组合物中的PapMV组分用作一种或多种抗原的佐剂和/或免疫刺激剂。 还提供了使用多价疫苗组合物来提供针对多种病原体菌株或针对多于一种病原体的保护。

公开(公告)号：US20090202983A1

公开(公告)日：2009-08-13

申请号：US12087820

申请日：2007-01-12

申请人： Holger Kost

发明人： Holger Kost

IPC分类号： C12Q1/70

CPC分类号： C12Q3/00 ,  C12N7/00 ,  C12N2760/16011 ,  C12N2760/16111 ,  C12N2760/16211 ,  C12Q1/04 ,  G01N33/56983 ,  G01N2333/07 ,  G01N2333/11

摘要： The invention provides a method for determining the concentration of virus particles and/or virus antigens in a sample. In particular, the invention relates to determining the concentration of influenza virus particles/influenza virus antigens in a sample. The invention further relates to the use of an ion-exchange matrix for the determination of the concentration of virus particles and/or virus antigens in a sample.

摘要翻译： 本发明提供了一种确定样品中病毒颗粒和/或病毒抗原浓度的方法。 特别地，本发明涉及确定样品中流感病毒颗粒/流感病毒抗原的浓度。 本发明还涉及离子交换基质用于测定样品中病毒颗粒和/或病毒抗原浓度的用途。